The EU has given Gilead the green light to market its twice-yearly pre-exposure prophylaxis (PrEP) product lenacapavir, which is viewed as a key part of the drugmaker's growth strategy in HIV. The ...
A junior varsity football game in Michigan became the center of controversy after a player was hospitalized with serious spine fractures following an on-field incident, prompting responses from both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback